


Earnings Presentation | Q3/9M-FY23




Global cybersecurity market overview






While the long-term growth of the industry is positive, we are witnessing headwinds in the medium-short term

Rapid digitization has enhanced need for greater cybersecurity investments





People enrolled in the world's largest unique digital identity program

SEGRITE



Quick Heal

Security Simplified

Users engaged in social media



Application downloads in 2020

30b



Average cost to subscriber per GB wireless data

Source: The Ministry of Electronics and Information Technology, TRAI, Government of India, Statista, Google report – Insights for Brands, KPMG Report – Fintech In India, India Data Diviner – Macquarie, Nokia MBIT, Goldman Sachs Investment Research – Portfolio Strategy Research (Sept 19, 2021)

Company at a glance






Empowering the team to solve business problems

To be the trusted by our customers in securing the digital world and aim to grow as reputable global market leader

Our Journey






Over 25 years of simplifying security

The Cash Cow: Retail Anti Virus Business



- Over 25 years into existence
- Market leadership with over 30% in the Indian market
- Robust Sales & Distribution network in India





Current Scenario:

- Market Headwinds in the short term: Sudden decrease in IT spending in the last quarter
- The trend is visible across the global software industry
- We foresee the same trend in the next couple of quarters


Our Approach:

- Focusing towards maintaining our market share in the period
- Drive consumer awareness in the geography in cybersecurity specific domain
- FY21 revenues included Rs. 30 crores of spillover revenues from FY20 due to Covid pandemic, hence FY22 numbers are not comparable to FY21

• Segmental revenues are regrouped basis end customers

The Growth Story: Enterprise Solutions

- Incubated the enterprise cybersecurity through internal accruals
- Growth story for QH in the years to come
- Enterprise solutions represent 95% of the cybersecurity market, which is growing at a CAGR of 11% while Quick Heal is growing at 20%





Ouick Heal

Business Momentum:

- Enterprise segment outperforming the market growth rates
- Established market fit for HawkkHunt: 5 customers onboarded
- HawkkProtect & HawkkScan currently in the process of establishing the product market fit
- New launches for all the products depicted above, planned in Q4 and revenues expected form Q2FY24.
- We are overlooking accelerated growth in the segment going forward

Future Outlook



Increasing R&D spend R&D team continuously working towards product upgrades with newer features. In FY22 R&D spends of 26%

Strong and Diversified Channel Network With 35,000+ channel partners, sales team Has deep market penetration 🛛 🗞

Innovation

Quick Heal lays strong emphasis innovation and evolving threats are addressed through timely updates of features.

ß

Quick Heal

•Û))

Security Simplified

Hiring the best

Focused on hiring the best employees to innovate, market and distribute its products globally



international clients





Q3/9M-FY23 EARNINGS HIGHLIGHTS

Q3-FY23 Earnings Highlights






9M-FY23 Earnings Highlights






Q3/9M-FY23 Consolidated Performance Highlights





Working Capital Analysis





- Calculation of Days = [(Particular heading/ TTM Sales) X (365 days)]
- Receivables have been considered net of Incentives

Q3-FY23 Income Statement



		Standalone			Consolidated		
PARTICULARS (₹ crs)	Q3-FY22	Q3-FY23	% change	Q3-FY22	Q3-FY23	% change	
Total Revenue	79.62	66.80	-16.10%	79.62	66.79	-16.11%	
Direct Cost	3.23	2.65		3.23	2.65		
Gross Profit	76.39	64.15	-16.02%	76.39	64.14	-16.04%	
Gross Margin	95.94%	96.03%		95.94%	96.03%		
Operating Cost							
Research and Development (R&D)	21.81	32.86		21.80	32.86		
Sales and Marketing (S&M)	21.74	26.19		22.04	26.19		
General Administration (G&A)	12.38	15.82		12.07	16.47		
Total Expenditure	55.93	74.87	-33.86%	55.91	75.52	-35.06%	
EBITDA	20.46	(10.72)	-152.39%	20.48	(11.38)	-155.58%	
EBITDA Margin	25.70%	-16.05%		25.72%	-17.04%	-42.76%	
Depreciation	4.55	4.17		4.54	4.17		
EBIT	15.91	(14.89)	-193.59%	15.94	(15.55)	-197.58%	
EBIT Margin	19.98%	-22.29%		20.01%	-23.28%		
Other Income	3.63	3.85		3.63	3.47		
Profit Before Tax (before exceptional item)	19.54	(11.04)	-156.50%	19.57	(12.08)	-161.74%	
Exceptional items	_	(0.10)		_	_		
Profit before Tax after exceptional items	19.54	(10.94)	-155.99%	19.57	(12.08)	-161.74%	
Тах	5.25	(2.78)		5.28	(2.78)		
Profit After Tax (PAT)	14.29	(8.16)	-157.10%	14.29	(9.30)	-165.10%	
PAT Margin	17.95%	-12.22%		17.94%	-13.92%		

NOTE: Certain figures have been re-grouped wherever necessary

9M-FY23 Income Statement

				Secu	irity Simplified	
PARTICULARS (₹ crs)		Standalone			Consolidated	
	9M-FY22	9M-FY23	% change	9M-FY22	9M-FY23	% change
Total Revenue	237.80	228.82	-3.78%	238.19	228.81	-3.94%
Direct Cost	9.31	8.74		9.03	8.74	
Gross Profit	228.49	220.08	-3.68%	229.16	220.07	-3.97%
Gross Margin	96.08%	96.18%		96.21%	96.18%	
Operating Cost						
Research and Development (R&D)	62.67	88.76		62.65	88.76	
Sales and Marketing (S&M)	59.15	67.26		60.04	67.27	
General Administration (G&A)	35.49	45.28		34.48	45.99	
Total Expenditure	157.31	201.30	-27.96%	157.17	202.02	28.54%
EBITDA	71.18	18.78	-73.62%	71.99	18.05	-74.93%
EBITDA Margin	29.93%	8.21%		30.22%	7.89%	-22.34%
Depreciation	12.80	12.26		12.80	12.26	
EBIT	58.38	6.52	-88.83%	59.19	5.79	-90.22%
EBIT Margin	24.55%	2.85%		24.85%	2.53%	
Other Income	13.51	12.42		13.53	12.07	
Profit Before Tax (before exceptional item)	71.89	18.94	-73.65%	72.72	17.86	-75.44%
Exceptional items	2.16	(0.10)		-	-	
Profit before Tax after exceptional items	69.73	19.04	-72.69%	72.72	17.86	-75.44%
Тах	17.53	4.79		17.62	4.82	
Profit After Tax (PAT)	52.20	14.25	-72.70%	55.10	13.04	-76.33%
PAT Margin	21.95%	6.23%		23.13%	5.70%	-17.43%

NOTE: Certain figures have been re-grouped wherever necessary

Quick Heal SEQRITE

Q3-FY23 Ratio analysis



	Stand	alone	Consolidated		
In %	Q3FY22	Q3-FY23	Q3-FY22	Q3-FY23	
Expenses					
Direct Cost / Revenue	4.06%	3.97%	4.06%	3.97%	
R&D / Revenue	27.39%	49.19%	27.38%	49.20%	
S&M / Revenue	27.30%	39.21%	27.68%	39.22%	
G&A / Revenue	15.55%	23.68%	15.16%	24.65%	
Total Cost / Revenue	70.25%	112.08%	70.23%	113.07%	
Margin					
Gross Margin	95.94%	96.03%	95.94%	96.03%	
EBITDA	25.70%	-16.05%	25.72%	-17.04%	
EBIT	19.98%	-22.29%	20.01%	-23.28%	
PBT	24.54%	-16.53%	24.57%	-18.09%	
PAT	17.95%	-12.22%	17.94%	-13.92%	

9M-FY23 Ratio analysis



	Stand	alone	Consolidated		
In %	9M-FY22	9M-FY23	9M-FY22	9M-FY23	
Expenses					
Direct Cost / Revenue	3.92%	3.82%	3.79%	3.82%	
R&D / Revenue	26.35%	38.79%	26.30%	38.79%	
S&M / Revenue	24.87%	29.39%	25.21%	29.40%	
G&A / Revenue	14.92%	19.79%	14.48%	20.10%	
Total Cost / Revenue	66.15%	87.97%	65.99%	88.29%	
Margin					
Gross Margin	96.08%	96.18%	96.21%	96.18%	
EBITDA	29.93%	8.21%	30.22%	7.89%	
EBIT	24.55%	2.85%	24.85%	2.53%	
PBT	30.23%	8.28%	30.53%	7.81%	
PAT	21.95%	6.23%	23.13%	5.70%	

Historical Annual Consolidated Income Statement



Security Simplified

PARTICULARS (INR Crs)	FY20	FY21	FY22	9M-FY23
Total Revenue	286.14	333.04	341.90	228.81
Direct Cost	12.41	13.70	13.84	8.74
Gross Profit	273.73	319.34	328.06	220.07
Gross Margins (%)	95.66%	95.89%	95.95%	96.18%
Operating Cost				
Total Expenditure	182.33	177.90	221.20	202.02
EBITDA	91.39	141.44	106.86	18.05
EBITDA Margins (%)	31.94%	42.47%	31.26%	7.89%
Depreciation	21.68	19.49	17.38	12.26
EBIT	69.71	121.95	89.48	5.79
EBIT Margins (%)	24.36%	36.62%	26.17%	2.53%
Other Income	31.59	24.16	19.20	12.07
Profit Before Tax (PBT)	101.31	146.11	108.68	17.86
Тах	26.90	39.16	25.49	4.82
Profit After Tax (PAT)	74.41	106.95	83.19	13.04
PAT Margins (%)	26.00%	32.11%	24.33%	5.70%
Basic & Diluted EPS (INR)	11.34	16.65	13.94	2.29


NOTE: Certain figures have been re-grouped wherever necessary


Capital Market Data





Price Data (as of 31 st December, 2022)				
Face Value	10.0			
Market Price	174.80			
52 Week H/L	251.1/143.95			
Market Cap (INR Mn)	9,277.25			
Equity Shares Outstanding (Mn)	53.08			
1 Year Avg. Trading Volume ('000)	131.55			
1 Year Avg. Net Turnover (Mn)	26.47			





Disclaimer



Quick Heal Technologies Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward-looking statements" based on the currently held beliefs and assumptions of the management of Quick Heal Technologies Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results to differ materially from the results, financial condition, performance, or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment, and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties, and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations, or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration therefrom.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness, and reasonableness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:

WALOREM ADVISORSMr. Anuj Sonpal
Valorem Advisors
Tel: +91-22-4903 9500
Email: guickheal@valoremadvisors.com

Investor Relations Officer

Mr. Deepak Kumar Deepak.Kumar01@quickheal.co.in

Company Secretary

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232 CIN No: L72200MH1995PLC091408 www.quickheal.co.in



Thank You